Glenmark Pharmaceuticals Limited — PPTs, 14-11-2024: Investor Presentation

**Financial Highlights:**

Glenmark Pharmaceuticals reported a consolidated revenue of ₹34,338 Mn for Q2 FY25, reflecting a year-over-year growth of 7.1%. The India and Europe segments demonstrated robust expansion, growing by 13.9% and 14.6% respectively. EBITDA for the quarter stood at ₹6,019 Mn, yielding an EBITDA margin of 17.5%. Notably, PAT reached ₹3,545 Mn, marking a marked recovery from a loss in the same quarter last year.

**Strategic Initiatives and Growth Drivers:**

Glenmark continues to strengthen its portfolio with strategic in-licensing of innovative products targeting unmet medical needs. The company is also progressing in the development of its novel biologic asset, ISB2001, which has shown promising results in Phase 1 trials.

**Business Developments:**

The company launched new products across various markets, including the respiratory segment, contributing to sustained growth in branded drugs. Efforts are ongoing to file additional ANDAs, enhancing market penetration.

**Market Position and Competitive Advantage:**

Glenmark ranks 13th in the Indian pharmaceutical market, outperforming the overall market growth, driven by strong performances in cardiac and dermatology segments. The company maintains a competitive edge through its diversified product offering and strong brand presence.

**Investor Implications:**

The company's positive trajectory in revenue and profitability, coupled with strategic initiatives in R&D, positions Glenmark well for potential growth. Investors should consider the ongoing expansion in both domestic and international markets as a key opportunity moving forward.